Table 1 Clinical characteristics of all patients in this study.
Characteristics | Mild (n = 34) | Severe (n = 33) | Children (n = 24) | P-value |
|---|---|---|---|---|
Age (y), median (IQR) | 37.8 (27.0–44.6) | 60.8 (38.8–75.9) | 7.4 (2.5–13.8) | 2.20e–14a |
Female sex, n (%) | 22 (64.7) | 17 (51.5) | 10 (41.7) | 0.21b |
Active or passive smoking, n (%) | 2 (5.9) | 6 (18.2) | 3 (12.5) | 0.08b |
Racial or ethnic group | ||||
Caucasian, n (%) | 28 (82.4) | 20 (60.6) | 17 (70.8) | 0.22b |
Non-caucasian, n (%) | 4 (11.8) | 1 (3.0) | 5 (20.8) | |
Days from symptom onset to sample collection | ||||
Days, median (IQR) | 18.0 (16.0–20.5) | 10.0 (7.5–14.0) | 15.0 (7.8–17.0) | 1.00e-04a |
Symptoms | ||||
Headache, n (%) | 32 (94.1) | 23 (69.7) | 13 (54.2) | 0.02b |
Myalgia, n (%) | 30 (88.2) | 20 (60.6) | 8 (33.3) | 1.83e-03b |
Malaise, n (%) | 28 (82.4) | 31 (93.9) | 14 (58.3) | 1.26e-03b |
Coryza, n (%) | 26 (76.5) | 18 (54.5) | 15 (62.5) | 0.21b |
Cough, n (%) | 25 (73.5) | 30 (90.9) | 16 (66.7) | 0.07b |
Fever, n (%) | 23 (67.6) | 26 (78.8) | 19 (79.2) | 0.51b |
Chills, n (%) | 21 (61.8) | 20 (60.6) | 9 (37.5) | 0.12b |
Dyspnea, n (%) | 20 (58.8) | 22 (66.7) | 4 (16.7) | 4.57e-04b |
Dysgeusia, n (%) | 20 (58.8) | 12 (36.4) | 6 (25.0) | 0.19b |
Sore throat, n (%) | 19 (55.9) | 12 (36.4) | 10 (41.7) | 0.32b |
Appetite loss, n (%) | 19 (55.9) | 21 (63.6) | 12 (50.0) | 0.56b |
Anosmia, n (%) | 19 (55.9) | 11 (33.3) | 6 (25.0) | 0.21b |
Stuffy nose, n (%) | 17 (50.0) | 11 (33.3) | 13 (54.2) | 0.33b |
Conjuctivitis, n (%) | 16 (47.1) | 10 (30.3) | 7 (29.2) | 0.28b |
Nausea, n (%) | 14 (41.2) | 12 (36.4) | 6 (25.0) | 0.64b |
Sputum production, n (%) | 12 (35.3) | 10 (30.3) | 6 (25.0) | 0.70b |
Diarrhea, n (%) | 12 (35.3) | 16 (48.5) | 7 (29.2) | 0.25b |
Vomiting, n (%) | 2 (5.9) | 4 (12.1) | 4 (16.7) | 0.42b |
Skin rash, n (%) | 1 (2.9) | 1 (3.0) | 1 (4.2) | 0.97b |
Underlying medical conditions | ||||
Obesity, n (%) | 10 (29.4) | 13 (39.4) | 0 (0.0) | 0.01b |
Hypertension, n (%) | 6 (17.6) | 15 (45.5) | 0 (0.0) | 1.00b |
Asthma, n (%) | 1 (2.9) | 2 (6.1) | 5 (20.8) | 3.77e-05b |
Diabetes mellitus, type 1 and 2, n (%) | 1 (2.9) | 11 (33.3) | 0 (0.0) | 0.04b |
Cancer, n (%) | 1 (2.9) | 2 (6.1) | 0 (0.0) | 0.73b |
Tuberculosis, n (%) | 0 (0.0) | 1 (3.0) | 0 (0.0) | 0.73b |
Stroke/CVA, n (%) | 0 (0.0) | 4 (12.1) | 0 (0.0) | 0.26b |
COPD, n (%) | 0 (0.0) | 4 (12.1) | 1 (4.2) | 0.43b |
Heart failure, n (%) | 0 (0.0) | 2 (6.1) | 0 (0.0) | 0.53b |
Congenital heart disease, n (%) | 0 (0.0) | 1 (3.0) | 0 (0.0) | 0.73b |
Ct value (median, IQR) | ||||
ORF1ab | 19.3 (16.7–22.6) | 24.3 (19.9–29.7) | 19.0 (15.4–27.5) | 0.05a |
S | 19.8 (16.7–23.0) | 25.3 (21.9–27.7) | 19.0 (13.2–28.3) | 0.02a |
N | 18.7 (16.1–23.5) | 24.0 (20.6–28.6) | 19.0 (14.1–29.2) | 0.02a |
Oxigen use | ||||
Oxigen use during hospitalization, n (%) | 0 (0.0) | 22 (66.7) | 0 (0.0) | 8.44e-12b |
